Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies

Digestive and Liver Disease

Volumn 45, Issue 7, 2013, Pages 543-551

  Frasinariu, Otilia E ^a   Ceccarelli, Sara ^b   Alisi, Anna ^b   Moraru, Evelina ^a   Nobili, Valerio ^b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Gut microbiome; Liver fibrosis; NAFLD; NASH

Indexed keywords

CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ANTHROPOMETRIC PARAMETERS; GUT LIVER AXIS; HEPATITIS; HUMAN; INTESTINE FLORA; LIVER FIBROSIS; MICROBIOME; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW; STEATOSIS;

EID: 84881222178     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.11.010     Document Type: Review

References (109)

1. Day C.P. Non-alcoholic fatty liver disease: a massive problem. Clinical Medicine 2011, 11:176-178.
2. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 2010, 7:195-203.
3. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
4. Day C.P. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. Digestive Diseases 2010, 28:255-260.
5. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
6. Pinzani M., Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Review of Gastroenterology and Hepatology 2010, 4:459-472.
7. Forbes S.J., Parola M. Liver fibrogenic cells. Best Practice and Research Clinical Gastroenterology 2011, 25:207-217.
8. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrossis: crosstalk between the liver and the gut. Journal of Physiology 2012, 590:447-458.
9. Seki E., De Minicis S., Osterreicher C.H., et al. TLR4 enhances TGF-beta signalling and hepatic fibrosis. Nature Medicine 2007, 13:1324-1332.
10. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139:323-334.
11. Gill S.R., Pop M., Deboy R.T., et al. Metagenomic analysis of the human distal gut microbiome. Science 2006, 312:1355-1359.
12. Eckburg P.B., Bik E.M., Bernstein C.N., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
13. Sandoval D.A., Seeley R.J. Medicine. The microbes made me eat it. Science 2010, 328:179-180.
14. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 2003, 112:1821-1830.
15. Kasturiratne A, Weerasinghe S, Dassanayake AS, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. Journal of Gastroenterology and Hepatology, , in press. doi:10.1111/j.1440-1746.2012.07264.x.
16. Kalliomäki M., Collado M.C., Salminen S., et al. Early differences in fecal microbiota composition in children may predict overweight. American Journal of Clinical Nutrition 2008, 87:534-538.
17. Spencer M.D., Hamp T., Reid R., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140:976-986.
18. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
19. Larkin T.A., Astheimer L.B., Price W.E. Dietary combination of soy with a probiotic or prebiotic food significantly reduces total and LDL cholesterol in mildly hypercholesterolaemic subjects. European Journal of Clinical Nutrition 2009, 63:238-245.
20. Xiao J.Z., Kondo S., Takahashi N., et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. Journal of Dairy Science 2003, 86:2452-2461.
21. Tannock G.W. A special fondness for lactobacilli. Applied and Environment Microbiology 2004, 70:3189-3194.
22. Musso G., Gambino R., Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Current Opinion in Lipidology 2010, 21:76-83.
23. Liu J., Wu D., Ahmed A., et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Current Microbiology 2012, 65:7-13.
24. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
25. Li T., Chiang J.Y. Bile Acid signaling in liver metabolism and diseases. Journal of Lipids 2012, 2012:754067.
26. Tanaka N., Matsubara T., Krausz K.W., et al. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56:118-129.
27. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, in press.
28. Hwang S.T., Cho Y.K., Park J.H., et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. Journal of Gastroenterology and Hepatology 2010, 25:562-567.
29. Stadlmayr A., Aigner E., Steger B., et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. Journal of Internal Medicine 2011, 270:41-49.
30. Touzin N.T., Bush K.N., Williams C.D., et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 2011, 4:169-176.
31. Wong V.W., Wong G.L., Tsang S.W., et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011, 60:829-836.
32. Tjalsma H., Boleij A., Marchesi J.R., et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nature Reviews Microbiology 2012, 10:575-582.
33. McGowan C.E., Jones P., Long M.D., et al. Changing shape of disease: nonalcoholic fatty liver disease in Crohn's disease-a case series and review of the literature. Inflammatory Bowel Diseases 2012, 18:49-54.
34. Hakansson A., Molin G. Gut microbiota and inflammation. Nutrients 2011, 3:637-682.
35. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annual Review of Immunology 2003, 21:335-376.
36. O'Neill L.A., Bowie A.G. The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology 2007, 7:353-364.
37. Alisi A., Carsetti R., Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011, 54:1500-1502.
38. Schwabe R.F., Seki E., Brenner D.A. Toll-like receptor signalling in the liver. Gastroenterology 2006, 130:1886-1900.
39. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
40. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
41. Takeda K., Akira S. TLR signalling pathways. Seminars in Immunology 2004, 16:3-9.
42. Guo J., Friedman S.L. Toll-like receptor 4 signalling in liver injury and hepatic fibrogenesis. Fibrogenesis and Tissue Repair 2010, 3:21.
43. Alisi A., Da Sacco L., Bruscalupi G., et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Laboratory Investigation 2011, 91:283-293.
44. Myokai F., Takashiba S., Lebo R., Amar S. A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning sequencingcharacterization chromosomal assignment. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:4518-4523.
45. Tang X., Metzger D., Leeman S., Amar S. LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: evidence for LITAF-dependent LPS signalling pathways. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:13777-13782.
46. Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends in Microbiology 2004, 12:186-192.
47. Freudenberg M.A., Tchaptchet S., Keck S., et al. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 2008, 213:193-203.
48. Kim H.M., Park B.S., Kim J.I., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130:906-917.
49. Miura K., Seki E., Ohnishi H., et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterology Research and Practice 2010, 362847.
50. Soares J.B., Pimentel-Nunes P., Roncon-Albuquerque R., et al. The role of lipopolysaccharide/toll-like receptor 4 signalling in chronic liver diseases. Hepatology International 2010, 4:659-672.
51. Abu-Shanab A., Quigley E.M.M. The role of the gut microbiota in non-alcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology 2010, 7:691-701.
52. Musso G., Gambino R., Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanism and implication for metabolic disorders. Current Opinion in Lipidology 2010, 21:76-83.
53. Yang S.Q., Lin H.Z., Lane M.D., et al. Obesity increases sensitivity to endotoxin liver injury: implications for then pathogenesis of steatohepatitis. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2557-2562.
54. Su L., Wang J.H., Cong X., et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chinese Medical Journal 2012, 125:306-311.
55. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose induced hepatic lipid accumulation in mice: role of endotoxin. Journal of Hepatology 2008, 48:983-992.
56. Velayudham A., Dolganiuc A., Ellis M., et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced non-alcoholic steatohepatitis model in mice. Hepatology 2009, 49:989-997.
57. Brun P., Castagliuolo I., Di Leo V., et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. American Journal of Physiology Gastrointestinal and Liver Physiology 2007, 292:518-525.
58. Rivera C.A., Adegboyega P., van Rooijen N., et al. Toll-like receptor-4 signalling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. Journal of Hepatology 2007, 47:571-579.
59. Spruss A., Kanuri G., Wagnerberger S., et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
60. Csak T., Velayudham A., Hritz I., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. American Journal of Physiology Gastrointestinal and Liver Physiology 2011, 300:433-441.
61. Sabaté J.M., Jouët P., Harnois F., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obesity Surgery 2008, 18:371-377.
62. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
63. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
64. Shanab A.A., Scully P., Crosbie O., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Digestive Diseases and Sciences 2011, 56:1524-1534.
65. Thuy S., Ladurner R., Volynets V., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. Journal of Nutrition 2008, 138:1452-1455.
66. Alisi A., Manco M., Devito R., et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. Journal of Pediatric Gastroenterology and Nutrition 2010, 50:645-649.
67. Harte A.L., da Silva N.F., Creely S.J., et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. Journal of Inflammation (London) 2010, 7:15.
68. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
69. Gäbele E., Mühlbauer M., Dorn C., et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochemical and Biophysical Research Communications 2008, 376:271-276.
70. Martin-Armas M., Simon-Santamaria J., Pettersen I., et al. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. Journal of Hepatology 2006, 44:939-946.
71. Su G.L., Klein R.D., Aminlari A., et al. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000, 31:932-936.
72. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. Journal of Hepatology 2009, 51:212-223.
73. Rabelo F., Oliveira C., Faintuch J., et al. Pro- and anti-inflammatory cytokines in Steatosis and Steatohepatitis. Obesity Surgery 2010, 20:906-912.
74. Tomita K., Tamiya G., Ando S., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut 2006, 55:415-424.
75. Kirsch R., Clarkson V., Verdonk R.C., et al. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. Journal of Gastroenterology and Hepatology 2006, 21:174-182.
76. Wagnerberger S., Spruss A., Kanuri G., et al. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. British Journal of Nutrition 2011, 10:1-12.
77. Gäbele E., Dostert K., Hofmann C., et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. Journal of Hepatology 2011, 55:1391-1399.
78. Ruiz A.G., Casafont F., Crespo J., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obesity Surgery 2007, 17:1374-1380.
79. Manco M., Marcellini M., Giannone G., et al. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. American Journal of Clinical Pathology 2007, 127:954-960.
80. Fujii H., Kawada N. Inflammation and fibrogenesis in steatohepatitis. Journal of Gastroenterology 2012, 47:215-225.
81. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Practice and Research. Clinical Gastroenterology 2011, 25:195-206.
82. Balsano C., Alisi A., Nobili V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. Current Drug Targets 2009, 10:505-512.
83. Lin R.S., Lee F.Y., Lee S.D., et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. Journal of Hepatology 1995, 22:165-172.
84. Chan C.C., Hwang S.J., Lee F.Y., et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scandinavian Journal of Gastroenterology 1997, 32:942-946.
85. Grinko I., Geerts A., Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. Journal of Hepatology 1995, 23:449-458.
86. Isayama F., Hines I.N., Kremer M., et al. LPS signalling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. American Journal of Physiology Gastrointestinal and Liver Physiology 2006, 290:1318-1328.
87. Bataller R., Brenner D.A. Liver fibrosis. Journal of Clinical Investigation 2005, 115:209-218.
88. Pradere J.P., Troeger J.S., Dapito D.H., et al. Toll-like receptor 4 and hepatic fibrogenesis. Seminars in Liver Disease 2010, 30:232-244.
89. Hua J., Qiu de K., Li J.Q., et al. Expression of Toll-like receptor 4 in rat liver during the course of carbon tetrachloride-induced liver injury. Journal of Gastroenterology and Hepatology 2007, 22:862-869.
90. Onichtchouk D., Chen Y.G., Dosch R., et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999, 401:480-485.
91. Sasaki T., Sasahira T., Shimura H., et al. Effect of Nma on growth inhibition by TGF-beta in human gastric carcinoma cell lines. Oncology Reports 2004, 11:1219-1223.
92. Luedde T., Trautwein C. A molecular link between inflammation and fibrogenesis: the bacterial microflora influences hepatic fibrosis via toll-like receptor 4-dependent modification of transforming growth factor-beta signalling in hepatic stellate cells. Hepatology 2008, 47:1089-1091.
93. Padgett K.A., Lan R.Y., Leung P.C., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. Journal of Autoimmunity 2009, 32:246-253.
94. Sekiya Y., Ogawa T., Yoshizato K., et al. Suppression of hepatic stellate cell activation by microRNA-29b. Biochemical and Biophysical Research Communications 2011, 412:74-79.
95. Roderburg C., Urban G.W., Bettermann K., et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011, 53:209-218.
96. Frances R., Zapater P., Gonzalez-Navajas J.M., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008, 47:978-985.
97. Li L., Chen L., Hu L., et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signalling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
98. Iacono A., Raso G.M., Canani R.B., et al. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. Journal of Nutritional Biochemistry 2011, 22:699-711.
99. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
100. Ma X., Hua J., Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. Journal of Hepatology 2008, 49:821-830.
101. Esposito E., Iacono A., Bianco G., et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. Journal of Nutrition 2009, 139:905-911.
102. Mencarelli A., Cipriani S., Renga B., et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 2012, 7:e45425.
103. Xu R.Y., Wan Y.P., Fang Q.Y., et al. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. Journal of Clinical Biochemistry and Nutrition 2012, 50:72-77.
104. Gratz S.W., Mykkanen H., El-Nezami H.S. Probiotics and gut health: a special focus on liver diseases. World Journal of Gastroenterology 2010, 16:403-410.
105. Zhu Q., Zou L., Jagavelu K., et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. Journal of Hepatology 2011, 56:893-899.
106. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. Journal of Clinical Gastroenterology 2005, 39:540-543.
107. Malaguarnera M., Vacante M., Antic T., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Digestive Diseases and Sciences 2012, 57:545-553.
108. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142:1592-1609.
109. Alisi A., Ceccarelli S., Panera N., et al. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Frontiers in Cellular and Infection Microbiology 2012, 2:132.